Research & Development

03 Nov 2020
- Drug Discovery
- Research & Development
Sanofi offers to acquire clinical-stage company Kiadis

By PBR Staff Writer

Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis for EUR 5.45 per share, representing an aggregate adjusted equity value of €308m.
03 Nov 2020
Drug Discovery
Research & Development
PerkinElmer to buy cell engineering firm Horizon Discovery for $383m

By PBR Staff Writer

US-based PerkinElmer has agreed to acquire UK-based cell engineering company Horizon Discovery Group in a deal valued at around $383m.
30 Oct 2020
Drug Discovery
Research & Development
Novartis buys gene therapy company Vedere Bio for up to $280m

By PBR Staff Writer

Swiss pharmaceutical company Novartis has acquired gene therapy company Vedere Bio in a deal valued at around $280m.
29 Oct 2020
Drug Discovery
Research & Development
Bristol Myers Squibb, insitro partner to develop treatments for neurodegenerative disorders

By PBR Staff Writer

Machine-learning driven drug discovery and development company insitro has entered into a five-year collaboration with Bristol Myers Squibb to develop treatments for neurodegenerative disorders.
29 Oct 2020
Drug Discovery
Research & Development
Novartis collaborates with Molecular Partners to develop two DARPin therapies designed for Covid-19

By PBR Staff Writer

Novartis and Molecular Partners announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.
27 Oct 2020
Drug Discovery
Research & Development
Bayer to acquire Asklepios BioPharmaceutical for up to $4bn

By PBR Staff Writer

German pharmaceutical and life sciences company Bayer has agreed to acquire US-based clinical-stage gene therapy company Asklepios BioPharmaceutical (AskBio) for up to $4bn.
23 Oct 2020
Drug Discovery
Research & Development
Sirnaomics seals $105m Series D financing for RNAi therapeutics

By PBR Staff Writer

Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing.
22 Oct 2020
Drug Discovery
Research & Development
EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi

By PBR Staff Writer

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland.
19 Oct 2020
Drug Discovery
Research & Development
Dren Bio announces a $60M Series A financing

By PBR Staff Writer

Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
16 Oct 2020
Drug Discovery
Research & Development
Eli Lilly to buy biotechnology firm Disarm Therapeutics

By PBR Staff Writer

Eli Lilly and Company has agreed to acquire privately-held biotechnology company Disarm Therapeutics for an upfront payment of $135m.

Drug Discovery

Research & Development

Formycon and Zydus sign exclusive agreement for FYB206 supply

Inductive Bio gains $21m ARPA-H funds for drug prediction models

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

Sanofi offers to acquire clinical-stage company Kiadis

PerkinElmer to buy cell engineering firm Horizon Discovery for $383m

Novartis buys gene therapy company Vedere Bio for up to $280m

Bristol Myers Squibb, insitro partner to develop treatments for neurodegenerative disorders

Novartis collaborates with Molecular Partners to develop two DARPin therapies designed for Covid-19

Bayer to acquire Asklepios BioPharmaceutical for up to $4bn

Sirnaomics seals $105m Series D financing for RNAi therapeutics

EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi

Dren Bio announces a $60M Series A financing

Eli Lilly to buy biotechnology firm Disarm Therapeutics

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found